HIV-1 vaccine - Sumagen

Drug Profile

HIV-1 vaccine - Sumagen

Alternative Names: Killed-whole HIV-1 vaccine; SAV-001; SAV-001H

Latest Information Update: 05 Sep 2013

Price : $50

At a glance

  • Originator University of Western Ontario
  • Developer Sumagen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 03 Sep 2013 HIV-1 vaccine - Sumagen is available for licensing as of 03 Sep 2013. http://www.sumagen.co.kr/english/
  • 03 Sep 2013 Immunogenicity & adverse events data from a phase I trial in HIV-1 infections released by Sumagen
  • 01 Sep 2013 Sumagen completes a phase I trial in HIV-1 infections in USA (NCT01546818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top